# Core 3: Pathology, Clinical Database, Sample Repository and Biomarkers

> **NIH NIH P01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $402,888

## Abstract

CORE 3 SUMMARY/ABSTRACT
Core 3 supports the clinically oriented translational studies in this PPG. In this renewal application, all
three projects share an integrated, synergistic focus on GI GVHD. Core 3 has developed new services
related to GI GVHD in order to meet this increased focus of all three projects. The first creates a
consolidated GI pathology core for both human and mouse samples and services all three projects.
These central pathology services provide continuity of analyses across species, ensuring that the
mechanistic studies in Projects 1 and 2 relate as closely as possible to the analysis of human samples
in Project 3.
The second new service creates a multi-center clinical database and repository, significantly expanding
the previous single center database and repository. We have assembled a consortium of eight major
transplant centers (four in the USA: University of Michigan, Ohio State University, Mayo Clinic, and
University of Pennsylvania; and four in Germany: Regensburg, Dresden, Hamburg, and Würzburg). Our
new consortium, called MAGIC (Michigan Acute GVHD International Consortium), will accelerate
research in GVHD by integrating clinical and laboratory findings from more than 800 allogeneic BMT
recipients annually. The linkage of biologic samples with detailed clinical data from multiple sites helps
ensure that our analyses and clinical trial results will be generalizable throughout the BMT community.
The third new service of this core builds upon the major accomplishment from the last cycle, the
development of the first validated GVHD biomarker-based grading system (Ann Arbor GVHD Grading).
Core 3 will perform the ELISA assays, including (for US centers) the real time Ann Arbor grading,
which is needed to identify eligible patients for experimental GVHD clinical treatment trial in Project 3.
Core 3 supports the translational studies in this PPG. In this renewal application, all three projects
share an integrated, synergistic focus on GI GVHD. Core 3 has developed new services related to GI
GVHD in order to meet this increased focus of all three projects. The first creates a consolidated GI
pathology core for both human and mouse samples and services all three projects. These central
pathology services provide continuity of analyses across species, ensuring that the mechanistic studies
in Projects 1 and 2 relate as closely as possible to the analysis of human samples in Project 3

## Key facts

- **NIH application ID:** 10006008
- **Project number:** 5P01CA039542-32
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** JOHN LEVINE
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $402,888
- **Award type:** 5
- **Project period:** 1997-09-10 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10006008

## Citation

> US National Institutes of Health, RePORTER application 10006008, Core 3: Pathology, Clinical Database, Sample Repository and Biomarkers (5P01CA039542-32). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10006008. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*